Inve India ▾

Granules India share price & results

Granules India Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q2 FY27
Ownership as of
Sept 2026

Hyderabad pharma maker of APIs, formulation intermediates, finished dosages and peptide CDMO services.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue802 ₹ crore−1.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin16.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit72.0 ₹ crore+4.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity14.80 %+0.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.45 %−2.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)24.84 %+20.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 18 judged targets kept · 12 open · verdicts reflect calls analysed to Q2 FY27.

Granules India Limited management guidance track record on Inve: 30 targets tracked across analysed earnings calls (6 achieved, 12 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA Marginabove 20% and improving
Call transcript, Q1 FY25 · 30 Jul 2024		Q1 FY25Q2 FY27:The strategic update confirmed EBITDA margin was 22%, maintaining the level well above the 20% target.
Call transcript, Q2 FY27 · 6 Oct 2026		Achieved
Production Disruption Durationslowdown on operation in Gagillapur will continue for a quarter or two
Call transcript, Q4 FY25 · 28 May 2025		Q4 FY25Q2 FY27:The facility is still awaiting FDA re-inspection in Q2 FY27, confirming the original 'quarter or two' guidance was significantly missed.
Call transcript, Q2 FY27 · 6 Oct 2026		Missed
Oncology Product Launchesstart in FY26
Call transcript, Q1 FY25 · 30 Jul 2024		Q1 FY25Q2 FY27:The strategic update in Q2 FY27 reiterated that oncology commercialization will begin in FY29, confirming the original FY26 target was missed.
Call transcript, Q2 FY27 · 6 Oct 2026		Revised Down

Source: Inve Guidance Tracker for Granules India Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

12 of Granules India Limited's 30 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 27 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹820.55 +3.25% · +₹25.8

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +45.3% 1Y

₹600₹700₹800₹900Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 23 Jan 2026Q4 FY26 — 29 Apr 2026Q1 FY27 — 21 Jul 2026Q2 FY27 — 6 Oct 2026

1Y: ₹564.55 on 24 Oct 2025 → ₹820.55. High ₹909.3 (11 Sept 2026), low ₹532.85 (24 Nov 2025).

Previous close
₹794.75
Market cap
₹22.4k Cr
52-week range
₹532.85 – ₹909.3
One year
+45.08%
Price to earnings (TTM to Jun 2026)
34.38×
Return on equity (TTM to Jun 2026)
14.80%

Overview

Symbol
NSE:GRANULES
Exchange
NSE
Currency
INR

What Granules India Limited does

Based on the company's own presentations, annual report and earnings calls.

Granules India is a vertically integrated pharmaceutical company spanning Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), Finished Dosages (FD) and, since the 2025 acquisition of Swiss peptide specialist Senn Chemicals, a Peptide CDMO business run through subsidiary Ascelis Peptides. It manufactures its own APIs and PFIs and forward-integrates these into finished formulations, giving it in-house control over the supply chain for products such as Paracetamol and Metformin as well as complex/high-barrier generics (e.g. ADHD stimulants, controlled substances, MUPS-technology products). It sells to pharmaceutical companies and retailers in North America, Europe, India, Latin America and other regulated and emerging markets, earning revenue from API/PFI/FD product sales and, increasingly, from CDMO manufacturing services for peptide-based therapeutics.

Segments

  • Finished Dosages (FD)
  • Active Pharmaceutical Ingredients (API)
  • Pharmaceutical Formulation Intermediates (PFI)
  • Peptide CDMO
Manufacturing facilities
10
Annual finished-dosage capacity
39 Bn+ dosages
API manufacturing capacity
39,360 TPA
Countries served
80+
Global customers
300+
Molecules in portfolio
100+
Founded 1991Headquarters Hyderabad, Telangana, IndiaEmployees 6,166 (FY2025 (31 Mar 2025)) Company website

How the price took the results

close before → close after

Q2 FY27
+2.3%
6 Oct
Q1 FY27
−0.0%
21 Jul
Q4 FY26
−0.1%
29 Apr
Q3 FY26
−1.1%
23 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Granules India Limited

Free account: one company. Everything above stays public.

Write why you follow Granules India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Granules India Limited

Guides on how to read this kind of business and the numbers that matter.